Illumina Lays Out Plans for Dx Sequencing as 454 also Considers Diagnostic Apps for Its Technology

Sequencing will play a prominent role in a three-pronged strategy Illumina has charted to develop diagnostic tests and services. Separately, 454 is also considering how to make its technology available for diagnostic use.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.